Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $287.00 Price Target at Wells Fargo & Company

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lifted by Wells Fargo & Company from $275.00 to $287.00 in a report published on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on ALNY. Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Canaccord Genuity Group raised their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Royal Bank of Canada restated an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $310.22.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $283.34 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39. The firm has a 50 day moving average of $257.16 and a two-hundred day moving average of $259.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ALNY. OneDigital Investment Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter worth about $281,000. Natixis Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter worth about $2,751,000. Mutual of America Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 26.7% during the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 405 shares in the last quarter. Pathstone Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 11.2% during the third quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock worth $1,719,000 after buying an additional 629 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Alnylam Pharmaceuticals during the third quarter worth about $902,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.